Drug Trial Radar · NCT03307785
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Last checked: Nov 20, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Oct 12, 2017
Primary completion
Feb 26, 2020
Study completion Dec 11, 2024
Sponsor
- Lead sponsor
- Tesaro, Inc.GSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 12, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part A: To test the safety and tolerability of combination therapy with Niraparib and TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part B: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel and TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part C: To test the safety and tolerability of combination therapy with Niraparib, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study. Part D: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study. Part E: To test the safety and tolerability of combination therapy with Carboplatin-Pemetrexed and TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part F: To test the safety and tolerability of combination therapy with Carboplatin-Pemetrexed, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part G: To test the safety and tolerability of combination therapy with Carboplatin-nab-Paclitaxel, TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part H: To test the safety and tolerability of combination therapy with Carboplatin-nab-Paclitaxel, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part I: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
Conditions
- Neoplasms
- Metastatic Cancer
- Advanced Cancer
- Solid Tumor
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer Stage IIIB
- Non Small Cell Lung Cancer
Interventions
NiraparibDrug
Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
TSR-042Drug
TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
Carboplatin-PaclitaxelDrug
Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer \[NSCLC\], ovarian cancer, endometrial cancer, and head and neck cancer.
BevacizumabDrug
Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.
TSR-022Drug
TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells. TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth.
Carboplatin-PemetrexedDrug
Pemetrexed and platinum therapy in combination with pembrolizumab (anti-PD-1 antibody) has proven to be efficacious in a first line setting for nonsquamous NSCLC patients
Carboplatin-Nab-PaclitaxelDrug
Nab-paclitaxel is a formulation of paclitaxel that is indicated for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Nab-paclitaxel has shown increased ORR and time to progression in metastatic breast cancer compared with solvent-based paclitaxel and has shown antitumor activity and improved ORR compared with solvent-based paclitaxel as first-line therapy in patients with NSCLC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Dose-limiting Toxicity (DLT)Time frame: 21 days
- Part B: Number of Participants With DLTTime frame: 21 days
- Part C: Number of Participants With DLTTime frame: 21 days
- Part D: Number of Participants With DLTTime frame: 21 days
- Part E: Number of Participants With DLTTime frame: 21 days
- Part F: Number of Participants With DLTTime frame: 21 days
- Part G: Number of Participants With DLTTime frame: 21 days
- Part H: Number of Participants With DLTTime frame: 21 days
- Part I: Number of Participants With DLTTime frame: 21 days
- Part A: Number of Participants With Non-serious Treatment-emergent Adverse Events (TEAEs), Serious TEAEs (STEAEs) and Adverse Events of Special Interest (AESIs)Time frame: Up to 28.5 months
- Part B: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 28.5 months
- Part C: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 22.5 months
- Part D: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 9.5 months
- Part E: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 4.4 months
- Part F: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 3.5 months
- Part G: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 24 months
- Part H: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 24 months
- Part I: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 24 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Scottsdale, Arizona
GSK Investigational Site
Encinitas, California
GSK Investigational Site
San Marcos, California
GSK Investigational Site
Sarasota, Florida
GSK Investigational Site
Canton, Ohio
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.